Results 21 to 30 of about 14,957,077 (381)

Long-term outcomes following CAR T cell therapy: what we know so far

Nature Reviews Clinical Oncology, 2023
Chimeric antigen receptors (CAR) are engineered fusion proteins designed to target T cells to antigens expressed on cancer cells. CAR T cells are now an established treatment for patients with relapsed and/or refractory B cell lymphomas, B cell acute ...
Kathryn M. Cappell, J. Kochenderfer
semanticscholar   +1 more source

CAR-T Cell Therapy [PDF]

International Journal of Molecular Sciences, 2020
CAR-T therapy has revolutionized the treatment of select hematological malignancies, namely, acute lymphoblastic leukemia and large B-cell lymphomas [...]
openaire   +2 more sources

Cancer Immunotherapy Using Chimeric Antigen Receptor Expressing T-Cells: Present and Future Needs of Clinical Cancer Centers

Frontiers in Immunology, 2020
Chimeric Antigen Receptor-T cells (CAR-T) are considered novel biological agents, designed to selectively attack cancer cells expressing specific antigens, with demonstrated clinical activity in patients affected with relapsed/refractory B-cell ...
Manuel Gotti, Irene Defrancesco, Mario D’Angelo, Sabrina Basso, Sabrina Basso, Luca Crotto, Alfredo Marinelli, Alfredo Marinelli, Cristina Maccalli, Vincenzo Iaconianni   +9 more
doaj   +1 more source

PiggyBac Transposon-Mediated CD19 Chimeric Antigen Receptor-T Cells Derived From CD45RA-Positive Peripheral Blood Mononuclear Cells Possess Potent and Sustained Antileukemic Function

Frontiers in Immunology, 2022
The quality of chimeric antigen receptor (CAR)-T cell products, namely, memory and exhaustion markers, affects the long-term functionality of CAR-T cells.
Masaya Suematsu, Shigeki Yagyu, Nobuyoshi Nagao, Susumu Kubota, Yuto Shimizu, Miyuki Tanaka, Yozo Nakazawa, Toshihiko Imamura   +7 more
doaj   +1 more source

Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System. [PDF]

, 2018
Chimeric antigen receptor (CAR) T cell therapy has proven clinically beneficial against B cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma. However, suboptimal clinical outcomes have been associated with decreased expansion and persistence of
Avanzi, Mauro P, Brentjens, Renier J, Cheung, Kenneth, Daniyan, Anthony F, Li, Xinghuo, Park, Hyebin, Purdon, Terence J, Spitzer, Matthew H, van Leeuwen, Dayenne G, Wijewarnasuriya, Dinali P, Yeku, Oladapo   +10 more
core   +1 more source

Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis. [PDF]

, 2018
Peritoneal metastasis (PM) is an advanced stage malignancy largely refractory to modern therapy. Intraperitoneal (IP) immunotherapy offers a novel approach for the control of regional disease of the peritoneal cavity by breaking immune tolerance.
Bowne, Wilbur B., Katz, Steven C., Khalili, Marian, Morano, William F., Richard, Scott D., Thadi, Anusha   +5 more
core   +2 more sources

Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. [PDF]

, 2014
The majority of chimeric antigen receptor (CAR) T-cell research has focused on attacking cancer cells. Here, we show that targeting the tumor-promoting, nontransformed stromal cells using CAR T cells may offer several advantages.
Albelda, Steven M., Antzis, Michael, Cotner, Cody E., Durham, Amy C., Johnson, Laura A., June, Carl H., Kapoor, Veena, Lo, Albert, Majumdar, Rajrupa S., Puré, Ellen, Scholler, John, Solomides, MD, Charalambos C., Sun, Jing, Wang, Liang-Chuan S.   +13 more
core   +2 more sources

Myeloid conditioning with c-kit-targeted CAR-T cells enables donor stem cell engraftment [PDF]

, 2018
We report a novel approach to bone marrow (BM) conditioning using c-kit-targeted chimeric antigen receptor T (c-kit CAR-T) cells in mice. Previous reports using anti-c-kit or anti-CD45 antibody linked to a toxin such as saporin have been promising.
Arai, Yasuyuki, Black, Mary A, Choi, Uimook, Corsino, Cristina I, Dinauer, Mary C, Feldman, Steven A, Koontz, Sherry M, Malech, Harry L, Sweeney, Colin L, Tajima, Masaki   +9 more
core   +2 more sources

CAR-T-Zellen erkennen und eliminieren den Thyreotropin-Rezeptor exprimierende differenzierte Schilddrüsenkarzinomzellen [PDF]

, 2020
Hintergrund: Das differenzierte Schilddrüsenkarzinom weist eine sehr gute Prognose auf. Dennoch gibt es Patienten, die refraktär auf die bereits etablier-ten Therapiemöglichkeiten der operativen Therapie, der Radioiodtherapie und der dauerhaften ...
Spieker, Nicola
core   +1 more source

CD38‐Specific CAR Integrated into CD38 Locus Driven by Different Promoters Causes Distinct Antitumor Activities of T and NK Cells

Advanced Science, 2023
The robust and stable expression of CD38 in T‐cell acute lymphoblastic leukemia (T‐ALL) blasts makes CD38 chimeric antigen receptor (CAR)‐T/natural killer (NK) a potential therapy for T‐ALL. However, CD38 expression in normal T/NK cells causes fratricide
Chan Liao, Yajie Wang, Yanjie Huang, Yanting Duan, Yan Liang, Jiangqing Chen, Jie Jiang, Kai Shang, Chun Zhou, Ying Gu, Nan Liu, Xun Zeng, Xiaofei Gao, Yongmin Tang, Jie Sun   +14 more
doaj   +1 more source